Biocat, BioRegion of Catalonia

🔬Noves infraestructures científiques a #Catalunya! Sis mesos després de la nostra primera publicació, actualitzem el mapa dels hubs i iniciatives científiques amb 7 noves infraestructures que impulsen la #innovació en el sector de la innovació en salut. Aquests nous espais fomenten la col·laboració entre institucions, empreses i centres de recerca, potenciant projectes d’alt impacte en ciències de la vida i la #salut. Descobreix les noves incorporacions a l’ecosistema científic català aquí 👉 https://lnkd.in/dYY82ckg

Biocat arrives at Bluesky! At Biocat we work to connect and boost the ecosystem of life sciences and health in #Catalonia, and we want to be present wherever our community is. That's why we expanded our digital presence and opened an account at Bluesky! Follow us to stay up to date on industry news, opportunities, events and everything that contributes to grow innovation in #health! Follow us and be part of the conversation! 👉 https://lnkd.in/eXW3Cptu

🗣️ Key takeaways from Fina Lladós Canela, President of Farmaindustria & GM of Amgen Iberia! During her intervention at the 2024 #BioRegionReport presentation in the roundtable “Anàlisi dels reptes i oportunitats sectorials”, she highlighted Catalonia’s strategic role as Europe’s second-largest biopharma hub, home to 1,500 companies. With regulatory changes underway at both European and local levels, she stressed the importance of leveraging this unique ecosystem for future growth. Key points: ✔️ Catalonia’s position as a top biopharma hub in Europe ✔️ A pivotal moment with evolving regulations ✔️ The need to seize this opportunity to drive innovation and expansion Watch her full intervention at the 2024 Bioregion Report presentation! 👉 https://lnkd.in/dJ-PmPG8

🎙️ Catalunya lidera el sector de la innovació en salut!   Capital Radio (Business) ha entrevistat a Robert Fabregat Fuentes, director general de Biocat. Fabregat ha analitzat l’estat de l’ecosistema de ciències de la vida i la #salut a #Catalunya, destacant-ne el creixement i la projecció internacional. A més, ha posat el focus en les teràpies avançades, una àrea estratègica on el territori vol consolidar-se com a hub d’innovació de referència a Europa i al món.   D’altra banda, ha avançat detalls de dues cites clau per al sector, que se celebraran enguany a la capital catalana: RESI Europe Barcelona 2025 (1-3 d’abril), una gran oportunitat per què la #innovació catalana es doni a conèixer davant d'inversors internacionals, i BIOSPAIN 2025 (7-9 d’octubre), que aspira a superar les xifres rècord del 2023.    Escolta l’entrevista completa aquí 👉 https://lnkd.in/dn5t8FPY

📢RESI Europe Barcelona 2025 is just around the corner! 🚨Only 4 days left! The leading early-stage investment event for life sciences and healthcare is happening from April 1 to 3, 2025! Organized by Life Science Nation with the support of Biocat, BioRegion of Catalonia, the Generalitat de Catalunya, and the Ajuntament de Barcelona, RESI Europe Barcelona will connect startups, scaleups, and global investors in a unique hybrid format. 🌍 What to expect? ✔️ +250 global investors focused on seed, Series A, and Series B funding ✔️ A unique 1:1 investor-to-startup ratio ✔️ Exclusive roundtables, workshops, and networking opportunities ✔️ Innovators Pitch Challenge (IPC): direct feedback from investors ✔️ Hybrid format: in-person at Hotel InterContinental Barcelona (April 1) + virtual sessions (April 2 to 3) 🚀 Don't miss the chance to be part of Europe's leading early-stage investment conference! Time is running out! Secure your spot now! 👉 https://lnkd.in/dVsUVhmb

🔝 What happened this March in the #BioRegion? March has been an exciting month for the #health innovation ecosystem, with groundbreaking research, major investments, and international recognition. The spotlight was on health startups at #4YFN25, and the momentum continues as #RESIEurope 2025 arrives in Barcelona on April 1st! 📌 Monthly highlights: ✔️ CONNECTA Therapeutics successfully completes Phase I clinical trial for CTH120. ✔️ SpliceBio launches Phase I/II trial for the first dual gene therapy for Stargardt disease. ✔️ KOA Biotech secures €2M to expand its biotechnology solutions. ✔️ Barcelona launches a €30M investment fund for strategic sectors. ✔️ Invivo Partners plays a key role in the €915M acquisition of EsoBiotec by AstraZeneca. ✔️ Asabys Partners reinvests in Agustine Therapeutics in a €78M funding round. ✔️ CNAG joins a European initiative to create the most comprehensive DNA catalog with a €45M budget. ✔️ Hospital Sant Pau integrates the most advanced robotic surgery system in Spain’s public healthcare sector. ✔️ Hospital Clínic de Barcelona opens two immersive virtual reality rooms to enhance mental health treatment. Want to explore this month’s top innovations and investments? Discover the picks of March here 👉 https://lnkd.in/du47_mwA

🌟 PRECISEU Best Practice Recognition 2025: Celebrating Innovation in Healthcare! Open Call! PRECISEU is excited to announce the Best Practice Recognition 2025, an initiative to highlight exceptional innovations in healthcare data utilization. This recognition will culminate in a ceremony during the General Assembly in Vilnius. The awards feature four categories: ✔️Impact: Academic-business partnerships improving #healthcare. ✔️Innovation: SMEs and startups advancing patient care with ATMPs. ✔️Culture: Organizations excelling in patient involvement. ✔️Excellence: Leaders in #health data accessibility and safety. Eligibility is open to public and private research-performing organizations from EU Member States or Horizon Europe-associated countries. Winners will receive Europe-wide recognition, mentoring opportunities, and participation in key conferences. 📝 Applications are now open! 🏆 Winners announced in September 📍 General Assembly in Vilnius Submission deadline: 25 April 2025 👉 https://lnkd.in/desfRmmF

🗣️ Valuable insights from Diego Angelino Velázquez, International Project Coordinator at TEM/Nordic Center for Sustainable Healthcare, during the recent discussion on sustainability in the #health sector. As a speaker at the 2024 #BioRegionReport presentation in the roundtable “Building a sustainable future advancement, challenges and future directions” Diego emphasized the need for more time to address the challenges of sustainability in healthcare, highlighting key points such as: ✔️ Complementarity: No process is isolated; we must consider interconnections within and outside the health sector. ✔️ Staff recognition: The role of healthcare professionals is vital for advancing sustainability initiatives. ✔️ Green financing: Connecting green financing to startups and small businesses is essential for developing innovative solutions. He’s insights remind us that collaboration and investment in sustainable practices are crucial for a resilient health sector. Watch his full intervention at the Bioregion report presentation! 👉 https://lnkd.in/dUrgp8aS

🔍 El Navegador Biocat segueix creixent! Ja hi ha més de 80 iniciatives disponibles a la BioRegió per impulsar la teva innovació! 🚀   Què pots trobar al Navegador Biocat? 🌱 Programes d’incubació i acceleració 💰 Accés a finançament públic i privat 🔬 Serveis de validació per a les teves innovacions   El Navegador Biocat és una eina pensada per trobar el suport que necessites segons l’estadi de desenvolupament i la tecnologia de les teves solucions en el marc del programa #PASS, una iniciativa de #Biocat, #CatSalut i l'Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) que pretén facilitar l'arribada de la #innovació al Sistema de Salut.   🏥 Hospitals i centres sanitaris! Si teniu programes o recursos per impulsar noves solucions en #salut, afegiu-los al Navegador i ajudeu a agilitzar la incorporació de les innovacions al sistema.   🔗 Per a més informació: https://lnkd.in/d2WaPxpM

📰 Asabys Partners reforça la seva aposta per Agustine Therapeutics La gestora de capital risc catalana especialitzada Asabys Partners ha tornat a invertir en la biotecnològica belga Agustine Therapeutics en una ronda de sèrie A per 78 milions d’euros. Aquesta operació, que va començar el juliol del 2024 amb una primera aportació de 17 milions, s’ha completat amb la incorporació de Novo Holdings i JEITO Capital com a nous inversors. Els fons es destinaran al desenvolupament clínic d’un tractament innovador per a la Charcot-Marie-Tooth Association, un grup de neuropaties que afecten el sistema nerviós perifèric. 📌 Via La Vanguardia